Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2022 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial...
May 09, 2022 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
April 26, 2022 16:10 ET | Source: ProQR Therapeutics N.V.

ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
April 13, 2022 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple...
March 23, 2022 16:30 ET | Source: ProQR Therapeutics N.V.

ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
March 07, 2022 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
February 28, 2022 08:30 ET | Source: Celsion Corporation

Celsion Corporation Announces Stock Consolidation

LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
November 11, 2021 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Webcast Virtual Analyst Event on November 18

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
November 04, 2021 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Third Quarter 2021 Operating and Financial Results

Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022Five-target collaboration with Lilly highlights significant potential of...
October 04, 2021 08:00 ET | Source: ProQR Therapeutics N.V.

ProQR Appoints Theresa Heggie as Chief Commercial Officer

Senior leader with extensive global rare disease commercialization experienceTop-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 ...